| Literature DB >> 26177022 |
Hui-Qin Tian1, Xin-Yuan Chen1, Ying Lu2, Wen-Min Lu1, Mei-Lin Wang3, Hai-Long Zhao4, Mei-Ping Lu1, Han Zhou1, Ruo-Xi Chen1, Zheng-Dong Zhang3, Chong Shen4, Lei Cheng5.
Abstract
As recent studies have described an association between vitamin D and allergic rhinitis, we hypothesized that vitamin D pathway-related genes may be candidate genes for susceptibility to allergic rhinitis. Thus, we sought to evaluate whether polymorphisms in the vitamin D receptor (VDR) and CYP2R1 genes are associated with mite-sensitized persistent allergic rhinitis (PER) in a Han Chinese population. A hospital-based case-control study consisting of 519 patients with mite-sensitized PER and 447 healthy controls was conducted. Five single nucleotide polymorphisms (SNPs) in VDR and CYP2R1 were selected for genotyping. The genotype and allele frequencies of rs9729, rs2228570, rs1544410, and rs731236 in VDR as well as rs2060793 in CYP2R1 were not significantly associated with susceptibility to mite-sensitized PER. After stratification analyses, however, both the CT and CT/TT genotypes of rs2228570 in VDR exhibited a significantly decreased risk (CT: adjusted odds ratio (OR)=0.58, 95% confidence intervals (CI)=0.37-0.91; CT/TT: adjusted OR=0.61, 95% CI=0.40-0.93) of mite-sensitized PER, while the AA genotype of rs2060793 in CYP2R1 exhibited a significantly increased risk (adjusted OR=1.85, 95% CI=1.03-3.34) of PER in the age subgroup of <16 years old. Both the AG and AG/GG genotypes of rs731236 in VDR exhibited a significantly decreased risk (AG: adjusted OR=0.43, 95% CI=0.21-0.89; AG/GG: adjusted OR=0.46, 95% CI=0.23-0.94) of PER in the female subgroup. Analysis of the locus-locus interactions of VDR and CYP2R1 revealed two models that involved combined SNPs of VDR and CYP2R1 were statistically significant (P<0.05). Our data suggest that age and gender may have an impact on the association of three SNPs (rs2228570, rs731236, and rs2060793) in genes of the vitamin D pathway with the risk of mite-sensitized PER in this Chinese population. The VDR and CYP2R1 variants may be involved in genetic interactions in the pathogenesis of PER.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26177022 PMCID: PMC4503713 DOI: 10.1371/journal.pone.0133162
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Distribution of selected variables between cases and controls.
| Variables | Cases (n = 519) | Controls ( |
| ||
|---|---|---|---|---|---|
| n | % | n | % | ||
| Age, median (IQR) | 16.0 (11.0–27.0) | 15.0 (9.9–29.0) | 0.453 | ||
| Gender | |||||
| Male | 345 | 66.5 | 277 | 62.0 | 0.145 |
| Female | 174 | 33.5 | 170 | 38.0 | |
| Concomitant asthma | |||||
| Yes | 118 | 27.0 | |||
| No | 319 | 73.0 | |||
| Serum total IgE (kU/L), median (IQR) | 254.6 (117.0–552.0) | 25.3 (10.5–47.8) | <0.001 | ||
| Allergen-specific IgE (kUA/L), median (IQR) | |||||
|
| 19.9 (4.9–46.3) | ||||
|
| 17.2 (5.1–43.8) | ||||
a Information of concomitant asthma was unavailable in some cases.
IQR: interquartile range.
Primary information about genotyped SNPs in VDR and CYP2R1.
| SNPs | Location | Base change | MAF |
| Genotyped (%) | ||
|---|---|---|---|---|---|---|---|
| NCBI | Case | Control | |||||
|
| |||||||
| rs9729 | 3’UTR |
| 0.317 | 0.279 | 0.272 | 0.806 | 99.9 |
| rs2228570 | Exon 2 |
| 0.366 | 0.463 | 0.490 | 0.806 | 99.8 |
| rs1544410 | Intron 8 |
| 0.061 | 0.048 | 0.049 | 0.282 | 99.4 |
| rs731236 | Exon 9 |
| 0.061 | 0.050 | 0.053 | 0.816 | 99.5 |
|
| |||||||
| rs2060793 | Promoter |
| 0.354 | 0.379 | 0.349 | 0.659 | 99.7 |
a MAF from the NCBI database (http://www.ncbi.nlm.nih.gov/SNP/).
b P-value compared in the control group to that expected by HWE.
SNPs, single nucleotide polymorphisms; VDR, vitamin D (1,25-dihydroxyvitamin D3) receptor (Homo sapiens [human]); CYP2R1, cytochrome P450, family 2, subfamily R, polypeptide 1 (Homo sapiens [human]); MAF, minor allele frequency; HWE, Hardy-Weinberg equilibrium; UTR, untranslated region.
Genotype and allele frequencies of VDR and CRY2R1 polymorphisms among cases and controls.
| Genotypes | Cases | Controls | Crude OR (95% CI) | Adjusted OR (95% CI) | ||
|---|---|---|---|---|---|---|
| n | % | n | % | |||
|
| ||||||
|
|
|
| ||||
|
| 266 | 51.4 | 236 | 52.8 | 1.00 | 1.00 |
|
| 215 | 41.5 | 179 | 40.0 | 1.07 (0.82–1.39) | 1.07 (0.82–1.39) |
|
| 37 | 7.1 | 32 | 7.2 | 1.03 (0.62–1.70) | 1.02 (0.62–1.70) |
|
| 252 | 48.6 | 211 | 47.2 | 1.06 (0.82–1.37) | 1.06 (0.82–1.37) |
| C allele | 1.04 (0.85–1.27) | 1.04 (0.85–1.23) | ||||
|
|
|
| ||||
|
| 147 | 28.4 | 115 | 25.7 | 1.00 | 1.00 |
|
| 261 | 50.5 | 226 | 50.6 | 0.90 (0.67–1.22) | 0.91 (0.67–1.23) |
|
| 109 | 21.1 | 106 | 23.7 | 0.80 (0.56–1.15) | 0.81 (0.56–1.16) |
|
| 370 | 71.6 | 332 | 74.3 | 0.87 (0.66–1.16) | 0.88 (0.66–1.17) |
|
| 0.90 (0.75–1.08) | 0.90 (0.75–1.08) | ||||
|
|
|
| ||||
|
| 470 | 90.7 | 399 | 90.3 | 1.00 | 1.00 |
|
| 46 | 8.9 | 43 | 9.7 | 0.91 (0.59–1.41) | 0.90 (0.58–1.39) |
|
| 2 | 0.4 | 0 | 0.0 | — | — |
|
| 48 | 9.3 | 43 | 9.7 | 0.95 (0.62–1.46) | 0.94 (0.61–1.45) |
|
| 0.99 (0.65–1.51) | 0.98 (0.64–1.49) | ||||
|
|
|
| ||||
|
| 469 | 90.5 | 397 | 89.6 | 1.00 | 1.00 |
|
| 46 | 8.9 | 45 | 10.2 | 0.87 (0.56–1.33) | 0.86 (0.56–1.33) |
|
| 3 | 0.6 | 1 | 0.2 | 2.54 (0.26–24.5) | 2.49 (0.26–24.1) |
|
| 9 | 9.5 | 46 | 10.4 | 0.90 (0.59–1.38) | 0.90 (0.59–1.37) |
|
| 0.94 (0.63–1.41) | 0.94 (0.63–1.41) | ||||
|
| ||||||
|
|
|
| ||||
|
| 201 | 38.7 | 186 | 41.9 | 1.00 | 1.00 |
|
| 243 | 46.8 | 206 | 46.4 | 1.11 (0.83–1.43) | 1.11 (0.84–1.46) |
|
| 75 | 14.5 | 52 | 11.7 | 1.34 (0.89–2.00) | 1.38 (0.92–2.08) |
|
| 318 | 61.3 | 258 | 58.1 | 1.14 (0.88–1.48) | 1.16 (0.90–1.51) |
|
| 1.14 (0.94–1.37) | 1.16 (0.96–1.39) | ||||
a Additive model.
b Adjusted for age and gender in logistic regression model.
c Thousand times permutation test.
VDR, vitamin D (1,25-dihydroxyvitamin D3) receptor (Homo sapiens [human]); CYP2R1, cytochrome P450, family 2, subfamily R, polypeptide 1 (Homo sapiens [human]); OR, odds ratio; CI, confidence interval.
Stratification analyses of VDR and CRY2R1 polymorphisms in PER subgroups.
| SNPs | Variables | Subgroup | N (cases/controls) | Adjusted OR (95% CI) | ||
|---|---|---|---|---|---|---|
| XY | YY | XY/YY | ||||
|
| ||||||
|
| ||||||
| Age (years) | <16 | 249/224 | 0.58(0.37–0.91) | 0.68(0.40–1.15) | 0.61(0.40–0.93) | |
| ≥16 | 268/223 | 1.38(0.91–2.10) | 0.94(0.57–1.54) | 1.22(0.82–1.80) | ||
| Gender | Male | 345/277 | 0.85(0.58–1.25) | 0.81(0.51–1.26) | 0.84(0.59–1.20) | |
| Female | 172/170 | 0.97(0.59–1.62) | 0.80(0.43–1.49) | 0.92(0.57–1.49) | ||
| Concomitant asthma | Yes | 118/447 | 1.06(0.63–1.77) | 1.03(0.56–1.90) | 1.05(0.64–1.72) | |
| No | 318/447 | 0.91(0.64–1.27) | 0.76(0.50–1.15) | 0.86(0.62–1.19) | ||
| Total IgE level | Lower | 456/447 | 0.87(0.64–1.19) | 0.81(0.56–1.17) | 0.85(0.63–1.14) | |
| Higher | 51/447 | 1.14(0.56–2.34) | 0.78(0.31–1.93) | 1.03(0.52–2.05) | ||
|
| ||||||
| Age (years) | <16 | 248/224 | 1.20(0.62–2.34) | 0.81(0.05–13.06) | 1.18(0.62–2.26) | |
| ≥16 | 270/219 | 0.67(0.38–1.20) | — | 0.73(0.41–1.28) | ||
| Gender | Male | 344/275 | 1.37(0.76–2.45) | 1.62(0.15–18.13) | 1.38(0.78–2.43) | |
| Female | 174/168 | 0.43(0.21–0.89) | — | 0.46(0.23–0.94) | ||
| Concomitant asthma | Yes | 117/443 | 0.82(0.38–1.76) | 2.53(0.16–41.08) | 0.88(0.42–1.83) | |
| No | 319/443 | 0.93(0.57–1.52) | 1.33(0.08–21.40) | 0.94(0.58–1.53) | ||
| Total IgE level | Lower | 457/443 | 0.87(0.55–1.36) | 1.89(0.17–21.03) | 0.89(0.57–1.38) | |
| Higher | 51/443 | 0.82(0.28–2.40) | 9.92(0.57–172.91) | 1.01(0.38–2.68) | ||
|
| ||||||
|
| ||||||
| Age (years) | <16 | 249/224 | 1.30(0.88–1.92) | 1.85(1.03–3.34) | 1.40(0.97–2.03) | |
| ≥16 | 270/220 | 0.92(0.64–1.35) | 0.98(0.55–1.72) | 0.93(0.64–1.34) | ||
| Gender | Male | 345/274 | 1.07(0.76–1.50) | 1.37(0.80–2.33) | 1.12(0.81–1.55) | |
| Female | 174/170 | 1.20(0.75–1.91) | 1.35(0.71–2.56) | 1.24(0.80–1.91) | ||
| Concomitant asthma | Yes | 118/444 | 1.05(0.67–1.64) | 1.33(0.69–2.58) | 1.11(0.72–1.68) | |
| No | 319/444 | 1.22(0.90–1.67) | 1.45(0.91–2.30) | 1.27(0.94–1.71) | ||
| Total IgE level | Lower | 458/444 | 1.11(0.84–1.47) | 1.35(0.89–2.05) | 1.15(0.88–1.51) | |
| Higher | 51/444 | 1.34(0.69–2.58) | 2.26(0.97–5.28) | 1.52(0.82–2.81) | ||
a Lower: below the 90th percentile of logarithmic total IgE level; Higher: above the 90th percentile of logarithmic total IgE level.
b Controls were stratified accordingly when dividing cases into age and gender subgroups, but they were kept as a whole in the situation of the other two subgroups, since the controls in the study had neither asthma nor higher total IgE level in the first place (see Table 1).
c Adjusted for age and gender in logistic regression model.
d Thousand times permutation test.
e XY: heterozygote genotype/wild-type genotype; YY: homozygote genotype/wild-type genotype; XY/YY: heterozygote genotype +homozygote genotype/wild-type genotype.
PER, persistent allergic rhinitis; VDR, vitamin D (1,25-dihydroxyvitamin D3) receptor (Homo sapiens [human]); CYP2R1, cytochrome P450, family 2, subfamily R, polypeptide 1 (Homo sapiens [human]); OR, odds ratio; CI, confidence interval.
Multifactor dimensionality reduction models for locus-locus interactions.
| Model | Training balance accuracy | Test balance accuracy | Cross-validation consistency |
|
|---|---|---|---|---|
| A5 | 0.5180 | 0.4938 | 8/10 | 0.6230 |
| A2 A5 | 0.5451 | 0.5199 | 10/10 | 0.3770 |
| A1 A2 A5 | 0.5788 | 0.5611 | 10/10 | 0.0107 |
| A1 A2 A4 A5 | 0.5926 | 0.5653 | 10/10 | 0.0107 |
| A1 A2 A3 A4 A5 | 0.5988 | 0.5539 | 10/10 | 0.1719 |
a The genotypes of rs9729, rs2228570, rs1544410, rs731236, and rs2060793 were renamed as A1, A2, A3, A4, and A5, respectively.
Primers and probes for genotype screening by TaqMan allelic discrimination.
| SNPs | Primers | Probes |
|---|---|---|
|
| ||
| rs9729 | F: | C: FAM- |
| R: | A: HEX- | |
| rs2228570 | F: | C: FAM- |
| R: | T: HEX- | |
| rs1544410 | F: | G: FAM- |
| R: | A: HEX- | |
| rs731236 | F: | A: FAM- |
| R: | G: HEX- | |
|
| ||
| rs2060793 | F: | G: FAM- |
| R: | A: HEX- |
a SNP position in NCBI dbSNP (http://www.ncbi.nlm.nih.gov/SNP/).
SNPs, single nucleotide polymorphisms; VDR, vitamin D (1,25-dihydroxyvitamin D3) receptor (Homo sapiens [human]); CYP2R1, cytochrome P450, family 2, subfamily R, polypeptide 1 (Homo sapiens [human]).